Milestone Pharmaceuticals is trading 5.51% down at $0.99, with no clearly reported company-specific catalyst identified for the decline.
- No new company-specific announcement or analyst action was found on September 11, 2026.
- A September 8 Wells Fargo presentation discussed CARDAMYST commercialization and international expansion but did not explicitly explain the move.
- Broader markets are rising, and coverage remains limited.